{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"16.1","value":"13"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"8.1","value":"7.4"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"7.9","value":"5.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"PFS was defined as the time from the first dose date to the start of disease progression or participant death (any cause), whichever occurred first. Disease progression was classed as either a disease progression observed as a response assessment, or a disease progression or symptomatic deterioration at treatment/study discontinuation. Participants who did not have disease progression or had not died were censored at the last known time that the participant was progression free. Disease progression was considered according to RECIST version 1.1 for Phase 2 Ewing's sarcoma and rhabdomyosarcoma participants. (For Phase 2 neuroblastoma participants who had both RECIST 1.1 and Curie score tumor evaluations, both tumor responses results were considered and an overall response was derived.) Median PFS time was estimated through Kaplan-Meier methods. 95% confidence interval about the median time to PFS event was obtained using Greenwood's method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ewing's Sarcoma"},{"description":"Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG001","title":"Phase 2: Neuroblastoma"},{"description":"Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG002","title":"Phase 2: Rhabdomyosarcoma"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population: participants who met eligibility criteria for Phase 2, completed at least 1 dose of study drug, and had baseline and at least 1 postbaseline efficacy assessment if having not discontinued the investigational product prior to postbaseline efficacy assessment due to disease progression or systematic deterioration.","reportingStatus":"POSTED","timeFrame":"Median treatment duration in Phase 2 per group: Ewings Sarcoma = 14 weeks (3-31), Neuroblastoma = 7 weeks (3-23), Rhabdomyosarcoma = 5 weeks (1-13). Participants were followed until disease progression (if applicable) up to a maximum of 100.3 weeks.","title":"Phase 2: Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}